Janssen‘s new under-the-skin formulation of daratumumab, called Darzalex Faspro, has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, as a faster and easier alternative to treat people with multiple myeloma. The new formulation, combining daratumumab and hyaluronidase, is given to patients by a healthcare provider as an abdominal injection that takes a few minutes. It is seen as an equally effective…
You must be logged in to read/download the full post.
The post CHMP Favors EU Approval of Darzalex Faspro as Faster Injection Therapy for Myeloma appeared first on BioNewsFeeds.